Grateful for the opportunity to present my poster at the @UlfUnited conference! It's been an honor collaborating with our incredible team @KennedyKrieger . Special thanks to Ann Moser, an exceptional and kindhearted leader, and a true pioneer in this field. #rarediseases#ULF
🧵 1/10 | Excited to share our State-of-the-Art Review in @JACCJournals#JACCCardioOnc! 🎉🫀
📖 “Management and Surveillance of Immune Checkpoint Inhibitor Myocarditis: Managing the Aftermath”
Huge thanks to our incredible mentors Drs. @A_SteinMerlob & @datsunian, and our amazing chief resident and co-first author @Tylermorad for their invaluable guidance and support throughout this work! 🙏🫀Special thanks to @qicong_sheng for the wonderful interview! 🎙️ @DOM_UCLA@uclaCVfellows@uclaimchiefs@UCLA@UCLAHealth
🔗 https://t.co/LMePdbDoF8
#CardioOnc #Immunotherapy #Myocarditis
Huge thanks to @DOM_UCLA for featuring our @JAMACardio work on optimizing quadruple GDMT in HFrEF!
Congratulations to @qicong_sheng , on his important #JACCAdvances work showing another side of the GDMT challenge! 👏
Together, these studies highlight complementary opportunities to improve GDMT delivery:
🔹 In >50,000 older adults hospitalized with HFrEF, optimal quadruple GDMT was projected to reduce hospitalization-related spending by ~$9,780 per patient over 1 year.
🔹 Many lower-cost quadruple-therapy regimens could fully offset their medication costs and result in net savings.
https://t.co/QLns4LXvSc
🔹 Qicong’s work showed that proactive, dashboard-directed outreach can identify patients with important treatment gaps and enable GDMT initiation or optimization.
🔹 Among eligible patients, overall GDMT and SGLT2i optimization significantly improved, supporting a shift from reactive care toward proactive population-health management.
https://t.co/vtEQyNbiPC
Deeply grateful to Dr. @gcfmd and Dr. @boback for their invaluable mentorship and support across these projects. 🙏🫀
@uclaCVfellows@uclaimchiefs@UCLAHealth
Huge congratulations to Professor @gcfmd on this incredibly well-deserved honor! 🏆His dedication to advancing and optimizing GDMT has had a tremendous impact on heart failure care and continues to inspire trainees across the field. Grateful for his invaluable mentorship, guidance, and support. @HFSA@DOM_UCLA@UCLAHealth
Heading to #AHA26 in Chicago?🫀🏙️ Join us to hear about our work on the cardiovascular toxicity landscape of tumor-infiltrating lymphocyte (TIL) therapy!
📅 Nov 9 | ⏰ 11:48 AM
📍 Session HF.MDP.24, Clinical Science Zone 2
Grateful to Drs. @A_SteinMerlob and @datsunian for their support and mentorship! 🙏@uclaCVfellows@DOM_UCLA@uclaimchiefs@UCLAHealth@AHAScience #Cardiooncology